Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25291012 | 0.85 | KCNMA1 (0.67) | EPHX1NPC1RAB9AKCNMA1ALDH1A1 | |
| SCHEMBL25247901 | 0.82 | EPHX1 (0.63) | EPHX1NPC1RAB9AKCNMA1ALDH1A1 | |
| SCHEMBL25298861 | 0.81 | EPHX1 (0.61) | EPHX1NPC1RAB9AKCNMA1ALDH1A1 | |
| SCHEMBL25287354 | 0.81 | EPHX1 (0.64) | EPHX1NPC1RAB9AKCNMA1ALDH1A1 | |
| SCHEMBL25248057 | 0.81 | EPHX1 (0.64) | EPHX1KCNMA1ALDH1A1MAPTKDM4E | |
| SCHEMBL30831348 | 0.81 | KCNMA1 (0.67) | EPHX1NPC1RAB9AKCNMA1ALDH1A1 | |
| SCHEMBL25295669 | 0.80 | EPHX1 (0.63) | EPHX1KCNMA1ALDH1A1MAPTKDM4E | |
| SCHEMBL25250292 | 0.79 | EPHX1 (0.56) | EPHX1NPC1RAB9AKCNMA1ALDH1A1 | |
| SCHEMBL11224174 | 0.79 | CXCR2 (0.60) | NPC1RAB9AALDH1A1MAPTKDM4E | |
| SCHEMBL25298506 | 0.78 | EPHX1 (0.60) | EPHX1KCNMA1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100980-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2025-03-27 | — | — | US | disclosed |
| WO-2023121022-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | 이화여자대학교 산학협력단 | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100980-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | LTB4R2, LTB4R, CYSLTR2 | EPHX1 197/4885NPC1 1534/4885RAB9A 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.